Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Douglas A. McIntyre | Sep 20, 2015 at 8:26 AM EDT

Why Warren Buffett Will Live to Be 90

courtesy of WhiteHouse.govActuaries preside over a weird science. Part of their jobs is to forecast how long people will live,…

Chris Lange | Sep 19, 2015 at 9:05 AM EDT

Top 6 Biotech Movers From the Past Week

ThinkstockOver the past week, a few biotech companies made absolutely massive runs and some had serious falls. In the past…

Chris Lange | Sep 18, 2015 at 12:55 PM EDT

Vascular Biogenics Rises on Presentation Hype

Vascular Biogenics was one of the leading stocks in the health care sector Friday, following news that the company will…

Chris Lange | Sep 18, 2015 at 11:45 AM EDT

Why Merrill Lynch Sees More Upside in Eli Lilly

Merrill Lynch reiterated a Buy rating and price objective on Eli Lilly after positive data on its Jardiance.

Paul Ausick | Sep 18, 2015 at 11:35 AM EDT

Penumbra IPO Soars After Pricing Above Range

Penumbra priced its initial public offering of 4 million shares at $30 per share on Thursday night, and the stock…

Chris Lange | Sep 18, 2015 at 9:05 AM EDT

Tracon Pharmaceuticals Surges With Positive Study

Tracon Pharmaceuticals made waves in the market on Friday morning, not so much due to one trial but really one…

Chris Lange | Sep 17, 2015 at 2:49 PM EDT

Nabriva Sets Price for IPO

ThinkstockNabriva Therapeutics A.G. has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding the anticipated…

Chris Lange | Sep 17, 2015 at 12:50 PM EDT

Why the Top Aerie Pharma Analyst Sees It Rising Even More

A Canaccord Genuity analyst has a Buy rating on Aerie Pharmaceuticals and increased the price target.

Chris Lange | Sep 17, 2015 at 10:50 AM EDT

Can-Fite Makes a Comeback With New FDA Designation

Can-Fite BioPharma is building momentum with its most recent designation from the FDA.

Chris Lange | Sep 17, 2015 at 9:55 AM EDT

Achillion Pharma Rises on Solid Interim Results

Its stock has suffered, but it is possible that Achillion’s interim trial results may have put the company back on…

Chris Lange | Sep 17, 2015 at 8:50 AM EDT

Is Aerie’s Move Sustainable?

Like many other companies in the health care industry, Aerie Pharmaceuticals lives and dies by the FDA's sword.

Chris Lange | Sep 16, 2015 at 1:45 PM EDT

RegenXBio Updates Anticipated Price for IPO

This is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.

Chris Lange | Sep 16, 2015 at 1:20 PM EDT

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

According to Fitch Ratings, biosimilars are beginning to take share from their reference biologics. This is seen in the debut…

Jon C. Ogg | Sep 16, 2015 at 1:10 PM EDT

Massive Numbers Aged 20 to 35 Still Go Without Health Insurance

The latest data from the U.S. Census Bureau on poverty, health insurance and income shows an alarming number of people…

Chris Lange | Sep 16, 2015 at 11:20 AM EDT

SynCardia Updates Terms for IPO

The expected price range for the SynCardia Systems IPO is $10 to $12 for 2.5 million shares.

1 … 244 245 246 247 248 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Warren Buffett Will Live to Be 90

Top 6 Biotech Movers From the Past Week

Vascular Biogenics Rises on Presentation Hype

Why Merrill Lynch Sees More Upside in Eli Lilly

Penumbra IPO Soars After Pricing Above Range

Tracon Pharmaceuticals Surges With Positive Study

Nabriva Sets Price for IPO

Why the Top Aerie Pharma Analyst Sees It Rising Even More

Can-Fite Makes a Comeback With New FDA Designation

Achillion Pharma Rises on Solid Interim Results

Is Aerie’s Move Sustainable?

RegenXBio Updates Anticipated Price for IPO

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

Massive Numbers Aged 20 to 35 Still Go Without Health Insurance

SynCardia Updates Terms for IPO

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Health and Healthcare Articles

All Health and Healthcare Articles

Why Warren Buffett Will Live to Be 90

Top 6 Biotech Movers From the Past Week

Vascular Biogenics Rises on Presentation Hype

Why Merrill Lynch Sees More Upside in Eli Lilly

Penumbra IPO Soars After Pricing Above Range

Tracon Pharmaceuticals Surges With Positive Study

Nabriva Sets Price for IPO

Why the Top Aerie Pharma Analyst Sees It Rising Even More

Can-Fite Makes a Comeback With New FDA Designation

Achillion Pharma Rises on Solid Interim Results

Is Aerie’s Move Sustainable?

RegenXBio Updates Anticipated Price for IPO

Fitch: Gradual Conversion Begins as First Biosimilar Hits US Market

Massive Numbers Aged 20 to 35 Still Go Without Health Insurance

SynCardia Updates Terms for IPO

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how